Interstitial Lung Disease Trial, By Invitation (NCT07363980)

Interstitial Lung Disease Trial, By Invitation NCT07363980 Sponsor: Ellen Margrethe Hauge Condition: Interstitial Lung Disease

Printed from Voxsanity (voxsanity.com.au) — NCT07363980 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Interstitial Lung Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with rheumatoid arthritis according to standard international diagnostic guidelines (confirm with trial site)
You have had at least one appointment at a rheumatology outpatient clinic in the last two years, either for diagnosing or monitoring your rheumatoid arthritis
You are between 50 and 75 years old

Who may not be able to join:

You have been diagnosed with another autoimmune disease affecting the whole body, other than a secondary condition called Sjögren's syndrome
You currently have active cancer
You have previously had a heart attack, a procedure to open blocked heart arteries (such as a stent), or heart bypass surgery
You have a known allergy to the dye used in certain medical scans (called radiocontrast agents)
Your kidneys are not working well enough, based on a specific blood test result (confirm exact threshold with trial site)
Your Body Mass Index (BMI) — a measure of body weight relative to height — is above 35
You have a persistent irregular heart rhythm condition called atrial fibrillation

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 22 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07363980

Sponsor: Ellen Margrethe Hauge

Phase: Not Applicable

Status: By Invitation

Condition: Interstitial Lung Disease

More information: https://clinicaltrials.gov/study/NCT07363980

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with rheumatoid arthritis according to standard international diagnostic guidelines (confirm with trial site)
You have had at least one appointment at a rheumatology outpatient clinic in the last two years, either for diagnosing or monitoring your rheumatoid arthritis
You are between 50 and 75 years old

Who may not be able to join:

You have been diagnosed with another autoimmune disease affecting the whole body, other than a secondary condition called Sjögren's syndrome
You currently have active cancer
You have previously had a heart attack, a procedure to open blocked heart arteries (such as a stent), or heart bypass surgery
You have a known allergy to the dye used in certain medical scans (called radiocontrast agents)
Your kidneys are not working well enough, based on a specific blood test result (confirm exact threshold with trial site)
Your Body Mass Index (BMI) — a measure of body weight relative to height — is above 35
You have a persistent irregular heart rhythm condition called atrial fibrillation

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

By Invitation

Phase

Not Applicable

Sponsor

Ellen Margrethe Hauge

Registry

ClinicalTrials.gov

Start date

21 February 2024

Est. completion

31 December 2038

Where this trial is recruiting

🇩🇰 Denmark

Primary endpoints

Number of participants with a first occurrence of Major Adverse Cardiovascular Events (MACE); Number of participants with a first occurrence of any ischemic cardiovascular events, including MACE; Number of participants with all-cause death (all-cause mortality)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov